Potrasertib

May 13, 2026 – IMPACT Therapeutics, Inc. (“IMPACT Therapeutics” or the “Company”), a commercial-stage biopharmaceutical company, today officially listed on the Main Board of The Stock Exchange of Hong Kong Limited (“HKEX”) under the stock code: 07630.HK. IMPACT Therapeutics offered 41,977,000 H shares (subject to the over-allotment option) priced at HK$20.1 per share. The total size of the Global Offering before exercise of the Over-allotment Option was HK$843.7 million (approximately US$107.8 million), and HK$970.3 million (approximately US$123.9 million) after full exercise of the Over-allotment Option. By market close on its debut day, IMPACT’s share price surged 108.3% to HK$41.86 per share. Dr. Tian Ye, CSO (left), and Dr. Cai Sui Xiong, CEO (right) The IPO featured a strong lineup. Goldman Sachs and CICC acted as Joint Sponsors. The cornerstone investor group was robust, with participation from Tencent, LAV, Foresight Funds, Nanjing Jiangbei New Area, First Quarter Moon OFC, and Exome Asset Management. This fully demonstrates the capital market’s high recognition and strong confidence in the Company’s core value, R&D capabilities, and long-term development prospects. The International Offering was 24.58 times oversubscribed, and the Hong Kong Public Offering was 2282.4 times oversubscribed, once again confirming the market’s high regard for IMPACT Therapeutics’ industry position and long-term growth potential. In line with the Company’s strategic plan, the net proceeds from the Global Offering will be primarily used to (a) fund the global clinical development, regulatory approvals, and commercialization of its core product, senaparib, (b) to fund the ongoing clinical development of its key products, IMP1734 and IMP9064, (c) to fund the research and development activities for other key pipeline assets; (d) to continuously develop its R&D platforms and to expand the drug pipeline; and (e) for working capital and other general corporate purposes. Dr. Sui Xiong Cai, Chief Executive Officer of IMPACT Therapeutics, commented: Today’s successful listing on the Main Board of the Hong Kong Stock Exchange represents a truly momentous milestone in our corporate journey. This achievement is the result of the unwavering dedication and relentless efforts of our entire team, and would not have been possible without the steadfast support of the Hong Kong Exchange, Nanjing Jiangbei New Area, the relevant provincial and municipal government authorities, our investors, and our professional advisors. With a commercial-stage product, a robust clinical pipeline, and two cutting-edge innovation technology platforms already in place, we are well-positioned to build on this strong foundation. Looking ahead, we will continue to advance our pipeline, expand strategic collaborations, and reinforce our core fundamentals, so as to generate sustainable, long-term value for the Company. About IMPACT Therapeutics Founded in 2009, we are a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients. We have in-house discovered and developed one of the most comprehensive and advanced SL franchises and are one of only three companies with both commercial-stage PARP1/2 inhibitors and clinical-stage next-generation PARP1-selective inhibitors worldwide. Our core product, Senaparib (IMP4297), has already been commercialized, following its approval as 1L maintenance therapy for OC “all-comers” in China in January 2025, and is reimbursable for OC 1L “all-comers” since January 1, 2026. Senaparib also delivered the most favorable PFS outcome among PARP1/2 inhibitors (non head-to-head) for 1L maintenance therapy for OC “all-comers” in China, setting a new benchmark in this class. Our major clinical pipeline drug candidates include the PARP1/2 inhibitor Senaparib (IMP4297), PARP1-selective inhibitors (IMP1734 and IMP1707, co-developed with Eikon Therapeutics), ATR inhibitor (IMP9064), WEE1 inhibitor (IMP7068), and multiple other synthetic lethality target inhibitors. Our continued growth is powered by an integrated R&D platform that enables innovation across both small molecules and emerging modalities, including ADCs and degraders. Additionally, we have forged partnerships with leading global biotech and China pharmaceutical companies to date, as validation of our pipeline and R&D platform. Risk Warning: Investors are advised to make prudent decisions, fully understand the inherent investment risks of the biopharmaceutical industry, and carefully read the “Risk Factors” section of the prospectus. This press release is for informational purposes only and does not constitute any investment advice or an offer to purchase securities. For additional information, please visit www.impacttherapeutics.com IMPACT Therapeutics Contact: +86 21 6841 1121 IR@impacttherapeutics.com PR@impacttherapeutics.com